Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Moderna Inc.

Start price
Target price
Perf. (%)
€139.80
21.01.22
€160.00
21.01.23
-2.00%
22.01.22

Revenue growth >5% per year expected
Differentiated customer and product portfolio
Future proof or reliable business model
Higher risks for its business
2U Inc.

Start price
Target price
Perf. (%)
€14.68
16.01.22
€14.00
16.01.23
-53.66%
17.01.23

Market Leader or Top 3
Small cyclical dependencies
Very Future proof/growth oriented business model
Little known brand
buy
Mercury Comp. Sys

Start price
Target price
Perf. (%)
€49.20
10.01.22
€60.00
10.01.23
17.89%
21.03.22

Could be worthwhile Investment >10% per year
Innovative
Known brand
buy
Novanta Inc

Start price
Target price
Perf. (%)
€141.00
10.01.22
€150.00
10.01.23
-8.51%
10.01.23

Could be worthwhile Investment >10% per year
Some uniques
Future proof or reliable business model
Higher risks for its business
Novocure Ltd

Start price
Target price
Perf. (%)
€59.26
09.01.22
€51.00
09.01.23
8.34%
16.03.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Silgan Holdings Inc.

Start price
Target price
Perf. (%)
€37.60
04.01.22
-
04.01.23
28.22%
05.01.23

buy
Roku

Start price
Target price
Perf. (%)
€198.52
30.12.21
€250.00
30.12.22
-81.15%
30.12.22

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
positive Cash Flow expected
buy
UFP Industries Inc.

Start price
Target price
Perf. (%)
€81.50
28.12.21
€85.00
28.12.22
-8.71%
29.12.22

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Revenue growth >5% per year expected
EBIT growth >5% per year expected
buy
Tandem Diabetes Care Inc

Start price
Target price
Perf. (%)
€136.00
28.12.21
€142.00
28.12.22
-70.42%
29.12.22

Could be worthwhile Investment >10% per year
Capable Management
Future proof or reliable business model
buy
Opko Health Inc.

Start price
Target price
Perf. (%)
€4.65
28.12.21
-
28.12.22
-75.54%
29.12.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Innovative
Future proof or reliable business model
buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€143.65
27.12.21
-
27.12.22
-9.78%
09.01.22

Risky Investment
buy
Sage Therapeutics Inc.

Start price
Target price
Perf. (%)
€37.99
27.12.21
€42.00
27.12.22
-5.05%
28.12.22

Could be worthwhile Investment >10% per year
buy
Moderna Inc.

Start price
Target price
Perf. (%)
€224.75
25.12.21
€260.00
25.12.22
-14.41%
06.01.22

Revenue growth >5% per year expected
Differentiated customer and product portfolio
Future proof or reliable business model
Higher risks for its business
buy
Zoom Video Communications Inc

Start price
Target price
Perf. (%)
€182.72
20.12.21
€162.00
20.12.22
-32.03%
24.01.22

Top 10 in its market
Future proof or reliable business model
negative Cash Flow expected
Significant cyclical dependencies
Moderna Inc.

Start price
Target price
Perf. (%)
€268.00
19.12.21
€135.00
19.12.22
-48.51%
19.09.22

buy
Neogen Corp.

Start price
Target price
Perf. (%)
€35.40
14.12.21
€38.00
14.12.22
-59.89%
15.12.22

Could be worthwhile Investment >10% per year
Arena Pharmaceuticals Inc

Start price
Target price
Perf. (%)
€81.50
13.12.21
-
13.12.22
1.23%
06.01.22

Probably not worthwhile Investment
buy
ON Semiconductor Corp

Start price
Target price
Perf. (%)
€59.06
13.12.21
€65.00
13.12.22
10.06%
14.12.22

Could be worthwhile Investment >10% per year
Future proof or reliable business model
High valuation
buy
Moderna Inc.

Start price
Target price
Perf. (%)
€232.00
12.12.21
-
12.12.22
-3.13%
25.12.21

Could be very worthwhile Investment >20% year
buy
Moderna Inc.

Start price
Target price
Perf. (%)
€232.00
12.12.21
€180.00
12.12.22
-32.76%
13.12.22

Could be worthwhile Investment >10% per year
Significant cyclical dependencies
buy
Moderna Inc.

Start price
Target price
Perf. (%)
€232.00
12.12.21
€260.00
12.12.22
-3.13%
25.12.21

Revenue growth >5% per year expected
Differentiated customer and product portfolio
Future proof or reliable business model
Higher risks for its business
Zoom Video Communications Inc

Start price
Target price
Perf. (%)
€163.02
05.12.21
€152.00
05.12.22
12.08%
20.12.21

Top 10 in its market
Future proof or reliable business model
negative Cash Flow expected
Significant cyclical dependencies
buy
DocuSign Inc.

Start price
Target price
Perf. (%)
€121.00
05.12.21
€188.00
05.12.22
-24.13%
28.03.22

buy
Moderna Inc.

Start price
Target price
Perf. (%)
€277.95
03.12.21
-
03.12.22
-54.18%
13.03.22

buy
Moderna Inc.

Start price
Target price
Perf. (%)
€274.00
01.12.21
€260.00
01.12.22
-15.33%
12.12.21

Revenue growth >5% per year expected
Differentiated customer and product portfolio
Future proof or reliable business model
Higher risks for its business